Agile's shares are heating up ahead of the company's Q1 earnings report.
News & Analysis: Agile Therapeutics
The biotech stock is getting hit hard by the marketwide downturn today. Here's why.
Agile's stock can't seem to find a bottom, despite a major regulatory approval earlier this month.
Shares drop after the company releases the pricing details of a recently announced capital raise.
Twirla now has a green light from the FDA. And that could mean a green light for investors looking for a promising small-cap biotech stock.
The drugmaker is borrowing money to tide it over until it can hopefully achieve commercial success for its first product.
Bargain-seeking investors might want to look at these three stocks before venturing into the risky world of penny stocks.
From a niche contraceptive to the world's top cancer treatment, the FDA has a number of interesting drugs it's reviewing this month.
Novavax, Agile Therapeutics, and Karyopharm Therapeutics are about to release registration-ready trial data.
Novavax, Agile Therapeutics, and Flexion Therapeutics have caught the fancy of some of the biggest investors on the planet, and after researching them, they're becoming favorites of mine, too.